3. Less common solid tumors of pancreas | ПРЕЦИЗИОННАЯ ОНКОЛОГИЯ

3. Less common solid tumors of pancreas



You need to register on site.  Post will be published after being moderated


Pancreatic adenocarcinoma arising from the ductal cells in the pancreas remains the most common pancreatic malignancy and accounts for 85–90% of all pancreatic neoplasms. While pancreatic adenocarcinoma has a poor prognosis, nonductal solid pancreatic tumors may be associated with a considerably better prognosis and can be differentiated from the more common adenocarcinoma based on imaging and pathological characteristics. This chapter reviews these less common solid tumors, including pancreatic neuroendocrine tumors (PNETs), acinar cell carcinomas (ACCs), solid pseudopapillary tumors (SPTs), primary pancreatic lymphomas (PPLs), and isolated pancreatic metastases.

Pancreatic neuroendocrine tumors

Neuroendocrine neoplasms of the pancreas were traditionally referred to as pancreatic carcinoids or islet cell tumors, assumed to arise from the islet cells, and were thought to have an indolent course. As the heterogeneous nature of this lesion was recognized, the term “neuroendocrine tumor” was proposed in place of “carcinoid” as it conveys the potential malignant nature and histopathology of the tumor more accurately [1]. These tumors are now classified as pancreatic neuroendocrine tumors (PanNETs) and are believed to be a group of epithelial neoplasms that are derived from multipotential stem cells of endodermal origin with predominant neuroendocrine differentiation [2]. PanNETs account for approximately 3% of all pancreatic neoplasms [3]. There is vast heterogeneity among these tumors; despite sharing a common histological appearance, they differ in biologic behavior, histologic differentiation, and functionality. PanNETs can be further categorized into functional and nonfunctional tumors based on the secretion of biologically active peptides and hormones, resulting in specific clinical syndromes [4, 5]. The WHO 2010 PanNET classification was revised to include mixed adenoneuroendocrine carcinomas, previously referred to as mixed-form carcinoid adenocarcinoma or mixed exocrine– endocrine carcinoma. This type of neoplasm is comprised of both adenocarcinoma and neuroendocrine carcinoma, with at least 30% of each component [6].


PanNETs are rare tumors with a reported incidence of 1–2 cases/106 population/year though a much higher rate ranging from 0.07 to 10% has been reported in surgical and autopsy series [7, 8]. This variation underscores the limitation in determining the exact incidence and prevalence of PanNETs as the majority of these tumors are small and indolent and may remain asymptomatic. Registry data from Europe, the United States, and Japan showed a rising incidence of these tumors, which probably correlates with the increased use of cross-sectional imaging and more frequent detection of incidental and asymptomatic tumors [9]. Older European studies report an incidence rate (per 100,000) of approximately 0.1 while more recent studies report an incidence rate of 0.3. A similar increase is reflected in the SEER database, with a rise in incidence from 0.17 (1970s) to 0.43 (2003–2007) [9]. A stratified sample survey in Japan reported a much higher incidence rate of 1.01/100,000, with a prevalence rate of 2.23/100,000 [10]. 24% of patients in this survey had an incidental diagnosis of their tumors.

The median age at diagnosis for PanNETs is 60 years, with a peak incidence rate occurring between the sixth and eighth decades. These tumors are slightly more common among men (53%) than women (47%) [11, 12]. Most PanNETs are nonfunctional and sporadic though they may be associated with hereditary endocrinopathies such as multiple endocrine neoplasia (MEN; Type 1), von Hippel–Lindau (VHL) disease, neurofibromatosis type 1 (NF1), and tuberous sclerosis [13]. Patients with these endocrinopathies have an increased risk of developing neuroendocrine tumors ranging from 35 to 75% of MEN 1, 20% for VHL disease, 10% for NF1, and 1% for tuberous sclerosis [5, 14]. In these patients, PanNETs tend to occur at a younger age, are multiple, and are likely to be diagnosed earlier because of surveillance in carriers of the mutations.

The incidence of functional PanNETs varies by tumor type with insulinoma being the most common (1–4 cases/106 population/year), followed by gastrinoma (0.5–2 cases/106 population/year), VIPoma (0.05–0.2 cases/106 population/year), and glucagonoma (0.01–0.1 cases/106 population/ year), respectively [12]. The true incidence of rarer types of PanNETs such as somatostatinoma, GRHoma, ACTHoma, and PTHrPoma is difficult to estimate given their rarity.

Since the majority of PanNETs are nonfunctional, most patients present at an advanced stage with mass effect or metastatic disease, and the 5-year survival has been reported between 27 and 62% [9]. The 5-year survival after surgical resection of noninsulinoma PanNETs has been reported as 65%, with a 10-year survival of 45% [15].


Functional PanNETs

Functionality of PanNETs depends on the clinical symptoms rather than the level or type of hormones secreted. Each type of functional PanNETs produces a distinct clinical hormonal hypersecretion syndrome, which will be described in detail later in this chapter.

Текст защищен. Пожалуйста, введите логин и паспорт или зарегистрируйтесь. Enter your username and password to gain access to this review.


  1. Capella C, Heitz PU, Hofler H, Solcia E, Kloppel G. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch. 1995;425(6):547–60.
  2. Sadaria MR, Hruban RH, Edil BH. Advancements in pancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol. 2013;7(5):477–90.
  3. Fesinmeyer MD, Austin MA, Li CI, De Roos AJ, Bowen DJ. Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(7):1766–73.
  4. Oberg K. Pancreatic endocrine tumors. Semin Oncol. 2010;37(6):594–618.
  5. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology. 2008;135(5):1469–92.
  6. Bosman FT. WHO classification of tumours of the digestive system. 4th ed. Lyon: International Agency for Research on Cancer; 2010. p. 417.
  7. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008;19(10):| 1727–33.
  8. Kimura W, Kuroda A, Morioka Y. Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases. Dig Dis Sci. 1991;36(7):933–42.
  9. Fraenkel M, Kim MK, Faggiano A, Valk GD. Epidemiology of gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol. 2012;26(6):691–703.
  10. Ito T, Sasano H, Tanaka M, Osamura RY, Sasaki I, Kimura W, et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol. 2010;45(2):234–43.
  11. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72.
  12. Yao JC, Eisner MP, Leary C, Dagohoy C, Phan A, Rashid A, et al. Population-based study of islet cell carcinoma. Ann Surg Oncol. 2007;14(12):3492–500.
  13. Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40(1):1–18. 1.
  14. Pieterman CR, Vriens MR, Dreijerink KM, van der Luijt RB, Valk GD. Care for patients with multiple endocrine neoplasia type 1: the current evidence base. Fam Cancer. 2011;10(1):157–71.
  15. de Wilde RF, Edil BH, Hruban RH, Maitra A. Welldifferentiated pancreatic neuroendocrine tumors: from genetics to therapy. Nat Rev Gastroenterol Hepatol. 2012;9(4):199–208.
  16. Vagefi PA, Razo O, Deshpande V, McGrath DJ, Lauwers GY, Thayer SP, et al. Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: the Massachusetts General Hospital experience from 1977 to 2005. Arch Surg. 2007;142(4):347–54.
  17. Cheema A, Weber J, Strosberg JR. Incidental detection of pancreatic neuroendocrine tumors: an analysis of incidence and outcomes. Ann Surg Oncol. 2012;19(9):2932–6.
  18. Madura JA, Cummings OW, Wiebke EA, Broadie TA, Goulet Jr RL, Howard TJ. Nonfunctioning islet cell tumors of the pancreas: a difficult diagnosis but one worth the effort. Am Surg. 1997;63(7):573–7. discussion 7–8.
  19. Matthews BD, Heniford BT, Reardon PR, Brunicardi FC, Greene FL. Surgical experience with nonfunctioning neuroendocrine tumors of the pancreas. Am Surg. 2000;66(12):1116–22. discussion 22–3.
  20. Service FJ, McMahon MM, O’Brien PC, Ballard DJ. Functioning insulinoma—incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc. 1991;66(7):711–9.
  21. DeVita Jr VT, Lawrence TS, Rosenberg SA, editors. DeVita, Hellman, and Rosenberg’s cancer: principles & practice of oncology. Philadelphia: Lippincott Williams & Wilkins; 2008. Available from: http://catd i r . l o c . g o v / c a t d i r / e n h a n c e m e n t s / fy0811/2008006079-d.html. http://catdir.loc.gov/catdir/enhancements/fy0811/2008006079-d.html, http:// www.lww.com/product/DeVita-Hellman-andRosenbergs-Cancer/?978-0-7817-7207-5.
  22. Placzkowski KA, Vella A, Thompson GB, Grant CS, Reading CC, Charboneau JW, et al. Secular trends in the presentation and management of functioning insulinoma at the Mayo Clinic, 1987–2007. J Clin Endocrinol Metab. 2009;94(4):1069–73.
  23. Berna MJ, Hoffmann KM, Serrano J, Gibril F, Jensen RT. Serum gastrin in Zollinger–Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine. 2006;85(6):295–330.



  1. Roy PK, Venzon DJ, Shojamanesh H, Abou-Saif A, Peghini P, Doppman JL, et al. Zollinger–Ellison syndrome. Clinical presentation in 261 patients. Medicine. 2000;79(6):379–411.
  2. Norton JA. Neuroendocrine tumors of the pancreas and duodenum. Curr Probl Surg. 1994;31(2):77–156.
  3. Gibril F, Doppman JL, Reynolds JC, Chen CC, Sutliff VE, Yu F, et al. Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and magnetic resonance image in their detection, frequency, location, and effect of their detection on management. J Clin Oncol. 1998;16(3):1040–53.
  4. Norton JA, Alexander HR, Fraker DL, Venzon DJ, Gibril F, Jensen RT. Possible primary lymph node gastrinoma: occurrence, natural history, and predictive factors: a prospective study. Ann Surg. 2003;237(5):650–7. discussion 7–9.
  5. Zollinger RM, Ellison EH. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. 1955. CA Cancer J Clin. 1989;39(4):231–47.
  6. Meriney DK. Pathophysiology and management of VIPoma: a case study. Oncol Nurs Forum. 1996;23(6):941–8. quiz 9–50.
  7. Bloom SR, Yiangou Y, Polak JM. Vasoactive intestinal peptide secreting tumors. Pathophysiological and clinical correlations. Ann N Y Acad Sci. 1988;527:518–27.
  8. Verner JV, Morrison AB. Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia. Am J Med. 1958;25(3):374–80.
  9. Perry RR, Vinik AI. Clinical review 72: diagnosis and management of functioning islet cell tumors. J Clin Endocrinol Metab. 1995;80(8):2273–8.
  10. Smith SL, Branton SA, Avino AJ, Martin JK, Klingler PJ, Thompson GB, et al. Vasoactive intestinal polypeptide secreting islet cell tumors: a 15-year experience and review of the literature. Surgery. 1998;124(6):1050–5.
  11. Friesen SR. Update on the diagnosis and treatment of rare neuroendocrine tumors. Surg Clin North Am. 1987;67(2):379–93.
  12. Lecorguille M, Hammel P, Couvelard A, O’Toole D, Ratouis A, Belghiti J, et al. [Jejunal vipoma]. Gastroenterologie clinique et biologique. 2004; 28(8–9):797–800.
  13. Wilkinson DS. Necrolytic migratory erythema with carcinoma of the pancreas. Trans St Johns Hosp Dermatol Soc. 1973;59(2):244–50.
  14. Boden G. Glucagonomas and insulinomas. Gastroenterol Clin North Am. 1989;18(4):831–45.
  15. Stacpoole PW. The glucagonoma syndrome: clinical features, diagnosis, and treatment. Endocr Rev. 1981;2(3):347–61.
  16. Pujol RM, Wang CY, el-Azhary RA, Su WP, Gibson LE, Schroeter AL. Necrolytic migratory erythema: clinicopathologic study of 13 cases. Int J Dermatol. 2004;43(1):12–8.
  17. Yamada T, Alpers DH. Textbook of gastroenterology. Hoboken: Blackwell; 2009. Available from: http://site.ebrary.com/id/10300962. Materials specified: ebrary http://site.ebrary.com/id/10300962.
  18. Harris GJ, Tio F, Cruz Jr AB. Somatostatinoma: a case report and review of the literature. J Surg Oncol. 1987;36(1):8–16.
  19. Soga J, Yakuwa Y. Somatostatinoma/inhibitory syndrome: a statistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas. J Exp Clin Cancer Res. 1999;18(1):13–22.
  20. Ehehalt F, Saeger HD, Schmidt CM, Grutzmann R. Neuroendocrine tumors of the pancreas. Oncologist. 2009;14(5):456–67.
  21. Filippella M, Davi MV, Doveri G, Lillaz E, Ciccarelli A, Massimetti E, et al. Hyperinsulinemic hypoglycemia associated with ectopic Cushing’s syndrome due to a pancreatic endocrine tumor in a Type 2 diabetes mellitus patient: clinical implications of a rare association. J Endocrinol Invest. 2011;34(3):175–9.
  22. Papazachariou IM, Virlos IT, Williamson RC. Parathyroid hormone-related peptide in pancreatic neuroendocrine tumours associated with hypercalcaemia. HPB (Oxford). 2001;3(3):221–5.
  23. Wu TJ, Lin CL, Taylor RL, Kvols LK, Kao PC. Increased parathyroid hormone-related peptide in patients with hypercalcemia associated with islet cell carcinoma. Mayo Clin Proc. 1997;72(12):1111–5.
  24. Nauck MA, Meier JJ. Diagnostic accuracy of an “amended” insulin–glucose ratio for the biochemical diagnosis of insulinomas. Ann Intern Med. 2012;157(11):767–75.
  25. Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV. The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine. 1996;75(2):53–63.
  26. Ardill JE, O’Dorisio TM. Circulating biomarkers in neuroendocrine tumors of the enteropancreatic tract: application to diagnosis, monitoring disease, and as prognostic indicators. Endocrinol Metab Clin North Am. 2010;39(4):777–90.
  27. Bajetta E, Ferrari L, Martinetti A, Celio L, Procopio G, Artale S, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer. 1999;86(5):858–65.
  28. Friesen SR, Tomita T, Kimmel JR. Pancreatic polypeptide update: its roles in detection of the trait for multiple endocrine adenopathy syndrome, type I and pancreatic polypeptide-secreting tumors. Surgery. 1983;94(6):1028–37.
  29. Nehar D, Lombard-Bohas C, Olivieri S, Claustrat B, Chayvialle JA, Penes MC, et al. Interest of chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxford). 2004;60(5): 644–52.
  30. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004;22(23):4762–71.
  31. Gouya H, Vignaux O, Augui J, Dousset B, Palazzo L, Louvel A, et al. CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. Am J Roentgenol. 2003; 181(4):987–92.
  32. Rockall AG, Reznek RH. Imaging of neuroendocrine tumours (CT/MR/US). Best Pract Res Clin Endocrinol Metab. 2007;21(1):43–68.
  33. Khashab MA, Yong E, Lennon AM, Shin EJ, Amateau S, Hruban RH, et al. EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors. Gastrointest Endosc. 2011;73(4):691–6.
  34. Ichikawa T, Peterson MS, Federle MP, Baron RL, Haradome H, Kawamori Y, et al. Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection. Radiology. 2000;216(1):163–71.
  35. Dromain C, de Baere T, Lumbroso J, Caillet H, Laplanche A, Boige V, et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol. 2005;23(1):70–8.
  36. Reidy-Lagunes DL, Gollub MJ, Saltz LB. Addition of octreotide functional imaging to cross-sectional computed tomography or magnetic resonance imaging for the detection of neuroendocrine tumors: added value or an anachronism? J Clin Oncol. 2011;29(3):e74–5.
  37. Sundin A. Imaging of neuroendocrine tumors. Expert Opin Med Diagn. 2012;6(5):473–83.
  38. Kim EY. Role of repeated endoscopic ultrasoundguided fine needle aspiration for inconclusive initial cytology result. Clin Endosc. 2013;46(5):540–2.
  39. Abboud B, Boujaoude J. Occult sporadic insulinoma: localization and surgical strategy. World J Gastroenterol. 2008;14(5):657–65.
  40. Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2012;95(2):98–119.
  41. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging handbook. 7th ed. Chicago: American Joint Committee on Cancer; 2010.
  42. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39(6):707–12.
  43. Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012;61(1):6–32.
  44. Reid MD, Balci S, Saka B, Adsay NV. Neuroendocrine tumors of the pancreas: current concepts and controversies. Endocr Pathol. 2014;25(1):65–79.
  45. Travis WD, Rush W, Flieder DB, Falk R, Fleming MV, Gal AA, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol. 1998;22(8): 934–44.
  46. Strosberg JR, Cheema A, Weber JM, Ghayouri M, Han G, Hodul PJ, et al. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications. Ann Surg. 2012;256(2):321–5.
  47. Strosberg JR, Cheema A, Weber J, Han G, Coppola D, Kvols LK. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol. 2011;29(22):3044–9.
  48. Papavramidis T, Papavramidis S. Solid pseudopapillary tumors of the pancreas: review of 718 patients reported in English literature. J Am Coll Surg. 2005;200(6):965–72.
  49. Yu PF, Hu ZH, Wang XB, Guo JM, Cheng XD, Zhang YL, et al. Solid pseudopapillary tumor of the pancreas: a review of 553 cases in Chinese literature. World J Gastroenterol. 2010;16(10):1209–14.
  50. Kato T, Egawa N, Kamisawa T, Tu Y, Sanaka M, Sakaki N, et al. A case of solid pseudopapillary neoplasm of the pancreas and tumor doubling time. Pancreatology. 2002;2(5):495–8.
  51. Madan AK, Weldon CB, Long WP, Johnson D, Raafat A. Solid and papillary epithelial neoplasm of the pancreas. J Surg Oncol. 2004;85(4):193–8.
  52. Tien YW, Ser KH, Hu RH, Lee CY, Jeng YM, Lee PH. Solid pseudopapillary neoplasms of the pancreas: is there a pathologic basis for the observed gender differences in incidence? Surgery. 2005;137(6):591–6.
  53. Abraham SC, Klimstra DS, Wilentz RE, Yeo CJ, Conlon K, Brennan M, et al. Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. Am J Pathol. 2002;160(4):1361–9.
  54. Maitra A, Weinberg AG, Schneider N, Patterson K. Detection of t(11;22)(q24;q12) translocation and EWS-FLI-1 fusion transcript in a case of solid pseudopapillary tumor of the pancreas. Pediatr Dev Pathol. 2000;3(6):603–5.
  55. Kosmahl M, Seada LS, Janig U, Harms D, Kloppel G. Solid-pseudopapillary tumor of the pancreas: its origin revisited. Virchows Arch. 2000;436(5):473–80.
  56. Klimstra DS. Nonductal neoplasms of the pancreas. Mod Pathol. 2007;20 Suppl 1:S94–112.
  57. Nishihara K, Nagoshi M, Tsuneyoshi M, Yamaguchi K, Hayashi I. Papillary cystic tumors of the pancreas. Assessment of their malignant potential. Cancer. 1993;71(1):82–92.
  58. Mortenson MM, Katz MH, Tamm EP, Bhutani MS, Wang H, Evans DB, et al. Current diagnosis and management of unusual pancreatic tumors. Am J Surg. 2008;196(1):100–13.
  59. Yao X, Ji Y, Zeng M, Rao S, Yang B. Solid pseudopapillary tumor of the pancreas: cross-sectional imaging and pathologic correlation. Pancreas. 2010;39(4):486–91.
  60. Wisnoski NC, Townsend Jr CM, Nealon WH, Freeman JL, Riall TS. 672 patients with acinar cell carcinoma of the pancreas: a population-based comparison to pancreatic adenocarcinoma. Surgery. 2008;144(2):141–8.
  61. Holen KD, Klimstra DS, Hummer A, Gonen M, Conlon K, Brennan M, et al. Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors. J Clin Oncol. 2002;20(24):4673–8.
  62. Kitagami H, Kondo S, Hirano S, Kawakami H, Egawa S, Tanaka M. Acinar cell carcinoma of the pancreas: clinical analysis of 115 patients from Pancreatic Cancer Registry of Japan Pancreas Society. Pancreas. 2007;35(1):42–6.
  63. Klimstra DS, Heffess CS, Oertel JE, Rosai J. Acinar cell carcinoma of the pancreas. A clinicopathologic study of 28 cases. Am J Surg Pathol. 1992;16(9):815–37.
  64. Schmidt CM, Matos JM, Bentrem DJ, Talamonti MS, Lillemoe KD, Bilimoria KY. Acinar cell carcinoma of the pancreas in the United States: prognostic factors and comparison to ductal adenocarcinoma. J Gastrointest Surg. 2008;12(12):2078–86.
  65. Abraham SC, Wu TT, Hruban RH, Lee JH, Yeo CJ, Conlon K, et al. Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway. Am J Pathol. 2002;160(3):953–62.
  66. Abraham SC, Wu TT, Klimstra DS, Finn LS, Lee JH, Yeo CJ, et al. Distinctive molecular genetic alterations in sporadic and familial adenomatous polyposisassociated pancreatoblastomas: frequent alterations in the APC/beta-catenin pathway and chromosome 11p. Am J Pathol. 2001;159(5):1619–27.
  67. Rigaud G, Moore PS, Zamboni G, Orlandini S, Taruscio D, Paradisi S, et al. Allelotype of pancreatic acinar cell carcinoma. Int J Cancer. 2000;88(5): 772–7.
  68. Hoorens A, Lemoine NR, McLellan E, Morohoshi T, Kamisawa T, Heitz PU, et al. Pancreatic acinar cell carcinoma. An analysis of cell lineage markers, p53 expression, and Ki-ras mutation. Am J Pathol. 1993;143(3):685–98.
  69. Seth AK, Argani P, Campbell KA, Cameron JL, Pawlik TM, Schulick RD, et al. Acinar cell carcinoma of the pancreas: an institutional series of resected patients and review of the current literature. J Gastrointest Surg. 2008;12(6):1061–7.
  70. Chiou YY, Chiang JH, Hwang JI, Yen CH, Tsay SH, Chang CY. Acinar cell carcinoma of the pancreas: clinical and computed tomography manifestations. J Comput Assist Tomogr. 2004;28(2):180–6.
  71. Tatli S, Mortele KJ, Levy AD, Glickman JN, Ros PR, Banks PA, et al. CT and MRI features of pure acinar cell carcinoma of the pancreas in adults. Am J Roentgenol. 2005;184(2):511–9.
  72. Zucca E, Roggero E, Bertoni F, Cavalli F. Primary extranodal non-Hodgkin’s lymphomas. Part 1: gastrointestinal, cutaneous and genitourinary lymphomas. Ann Oncol. 1997;8(8):727–37.
  73. Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer. 1972;29(1):252–60.
  74. Baylor SM, Berg JW. Cross-classification and survival characteristics of 5,000 cases of cancer of the pancreas. J Surg Oncol. 1973;5(4):335–58.
  75. Nishimura R, Takakuwa T, Hoshida Y, Tsujimoto M, Aozasa K. Primary pancreatic lymphoma: clinicopathological analysis of 19 cases from Japan and review of the literature. Oncology. 2001;60(4):322–9.
  76. Nayer H, Weir EG, Sheth S, Ali SZ. Primary pancreatic lymphomas: a cytopathologic analysis of a rare malignancy. Cancer. 2004;102(5):315–21.
  77. Behrns KE, Sarr MG, Strickler JG. Pancreatic lymphoma: is it a surgical disease? Pancreas. 1994;9(5): 662–7.
  78. Koniaris LG, Lillemoe KD, Yeo CJ, Abrams RA, Colemann J, Nakeeb A, et al. Is there a role for surgical resection in the treatment of early-stage pancreatic lymphoma? J Am Coll Surg. 2000;190(3):319–30.
  79. Saif MW. Primary pancreatic lymphomas. JOP. 2006;7(3):262–73.
  80. Merkle EM, Bender GN, Brambs HJ. Imaging findings in pancreatic lymphoma: differential aspects. Am J Roentgenol. 2000;174(3):671–5.
  81. Dawson IM, Cornes JS, Morson BC. Primary malignant lymphoid tumours of the intestinal tract. Report of 37 cases with a study of factors influencing prognosis. Br J Surg. 1961;49:80–9.
  82. Salman B, Brat G, Yoon YS, Hruban RH, Singhi AD, Fishman EK, et al. The diagnosis and surgical treatment of pancreatoblastoma in adults: a case series and review of the literature. J Gastrointest Surg. 2013;17(12):2153–61.
  83. Bien E, Godzinski J, Dall’igna P, Defachelles AS, Stachowicz-Stencel T, Orbach D, et al. Pancreatoblastoma: a report from the European cooperative study group for paediatric rare tumours (EXPeRT). Eur J Cancer. 2011;47(15):2347–52.
  84. Montemarano H, Lonergan GJ, Bulas DI, Selby DM. Pancreatoblastoma: imaging findings in 10 patients and review of the literature. Radiology. 2000;214(2):476–82.
  85. Roland CF, van Heerden JA. Nonpancreatic primary tumors with metastasis to the pancreas. Surg Gynecol Obstet. 1989;168(4):345–7.
  86. Adler H, Redmond CE, Heneghan HM, Swan N, Maguire D, Traynor O, et al. Pancreatectomy for metastatic disease: a systematic review. Eur J Surg Oncol. 2014;40(4):379–86.
  87. Ghavamian R, Klein KA, Stephens DH, Welch TJ, LeRoy AJ, Richardson RL, et al. Renal cell carcinoma metastatic to the pancreas: clinical and radiological features. Mayo Clin Proc. 2000;75(6):581–5.

WordPress: 86.63MB | MySQL:1044 | 3,050sec